Fig. 4
From: Development and evaluation of curcumin nano-niosomes for glioma-targeted therapy
In vivo evaluation of Cur-Nio and TF-Cur-Nio. (A) Schematic illustration of the in-situ tumor-bearing nude mouse model. (B) Morphological observation of tumors in nude mice. (C) Gross appearance of brains from nude mice with in-situ tumors. (D) H&E staining of glioma tissue: (a) whole brain tissue; (b) tumor tissue with no clear boundary to normal brain tissue; (c) normal brain tissue; (d) glioma tissue. (E) H&E staining of glioma tissues treated with different formulations: (a) Control; (b) Cur-solution; (c) Cur-Nio; (d) TF-Cur-Nio. (F) TUNEL staining analysis of glioma tissues treated with different formulations: (a) Control; (b) Cur-solution; (c) Cur-Nio; (d) TF-Cur-Nio (green: apoptotic cells; blue: nucleus). (G) Body weight changes in C6 tumor-bearing nude mice across different treatment groups (n = 8). (H) Survival curves of C6 tumor-bearing nude mice in different treatment groups (n = 8). (I) H&E-stained sections of various tissues and organs from treated mice. (J) Hemolysis assay of TF-Cur-Nio solutions at different concentrations mixed with red blood cells for 4 h: (a) 200 μg/mL; (b) 100 μg/mL; (c) 50 μg/mL; (d) 25 μg/mL; (e) 10 μg/mL; (f) negative control; (g) positive control.
